Everything below concerns Karl Fischer titration. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
is equal to zero, which means that for an incompressible fluid the flow velocity field is a solenoidal vector field or a divergence-free vector field. Note that this relationship can be expanded upon due to its uniqueness with the vector Laplace operator
In October 2025, Wander was indicted in the U.S. District Court for the Southern District of New York on federal charges of conspiracy to commit wire fraud, wire fraud, conspiracy to commit securities fraud, and securities fraud. Prosecutors alleged that Wander and his associates defrauded lenders and investors of nearly $500 million through a scheme involving fabricated financial statements, doctored records, and double-pledged collateral. New allegations were made in a superseding indictment on June 30, 2026, further alleging diversion of loan funds, fabrication of financial records, and witness tampering.
== Physiological functions == The sites of APLNR receptor expression are linked to the different functions played by Elabela in the organism. Despite that, Elabela is capable of signaling independently of APLNR in human embryonic stem cells and certain cancer cell lines including OVISE.
Sources: en.wikipedia.org
The widespread smoking of cigarettes in the Western world is largely a 20th-century phenomenon. By the late 19th century cigarettes were known as coffin nails but the link between lung cancer and smoking was not established until the 20th century. German doctors were the first to make the link, and it led to the first antitobacco movement in Nazi Germany.
=== Amputation as punishment === There is evidence of amputation as punishment dating back to 1750 BCE. The Babylonian Code of King Hammurabi sanctioned amputation as a punishment. Amputation as a punishment continued in ancient Peru, where the part of the body amputated had a connection to the crime committed (for example, stealing might be punished by amputating the hand of the guilty). Amputation continued as a form of punishment into the Roman period as well as the Byzantine period, but became less prominent after the collapse of the Byzantine Empire. These punishments increased again during the Middle Ages, but declined again after perceptions of punitive amputation changed significantly during the Renaissance and Enlightenment. In medieval Europe, corpses would sometimes be amputated after death as a form of public shaming or punishment. Medieval Christians believed strongly in the importance of bodily integrity, even after death; therefore, post-execution dismemberment reflected the expectation of eternal damnation for the worst criminals. There is also documentation of nose amputation being used as a form of punishment or retaliation. In France during the 5th and 6th centuries, nose cutting was prominent enough to be classified as its own crime, which would result in a serious fine to the perpetrator. However, it was also occasionally used as a punishment for serious crimes such as threatening royals.
== Haemovigilance == Haemovigilance is the set of surveillance procedures that monitors, reports, investigates, and analyses adverse events related to transfusion. It covers the entire blood transfusion chain, from blood donation and processing of blood and its components, through to their provision and transfusion to patients. These reporting systems play a fundamental role in enhancing patient safety by learning from failures and then putting system changes in place to prevent them in the future. The TP's involvement in haemovigilance within the hospital setting, starts with education of those involved in the transfusion process so they can recognise, manage, and report reactions. The TPs roles ensures clinical transfusion incidents, transfusion reactions, specimen labelling errors are investigated and report data to haemovigilance governance programmes (e.g. SHOT in the UK). By conducting process reviews and communicating directly with the relevant colleagues and patients, the TP can provide essential details that are needed to complete investigations. This information can assist with determining the transfusion reaction type and recommendations for future transfusion plans for the patient, or the implementation of corrective and preventative measures. National haemovigilance schemes e.g. SHOT provide the TP with a resource for educating clinical colleagues on transfusion safety and recommendations for best practice.
Sources: en.wikipedia.org
=== Total chemical synthesis === A complete organic synthesis pathway for the pyoverdine produced by P. aeruginosa strain PAO1 has been reported using solid-phase peptide synthesis. This protocol yielded pyoverdine at high yield (~48%) and is expected to substantially increase the ability of scientists to generate targeted derivatives on the pyoverdine scaffold and to facilitate the creation of siderophores with antimicrobial warheads.
Surgical correction of inguinal hernias is called a hernia repair. It is not recommended in minimally symptomatic hernias, for which watchful waiting is advised, due to the risk of post-herniorraphy pain syndrome. Surgery is commonly performed as outpatient surgery. Various surgical strategies may be considered in the planning of inguinal hernia repair. These include the consideration of mesh use (e.g., synthetic or biologic), open repair, use of laparoscopy, type of anesthesia (general or local), appropriateness of bilateral repair, etc. Mesh or non-mesh repairs have both benefits in different areas, but mesh repairs may reduce the rate of hernia reappearance, visceral or neurovascular injuries, length of hospital stay, and time to return to activities of daily living. In emergency surgery, it is currently uncertain if mesh or non-mesh repair works best. Laparoscopy is most commonly used for non-emergency cases; however, a minimally invasive open repair may have a lower incidence of post-operative nausea and mesh associated pain. During surgery conducted under local anaesthesia, the patient will be asked to cough and strain during the procedure to help in demonstrating that the repair is without tension and sound.
Vaginal anomalies are defects that result in an abnormal or absent vagina. The most common obstructive vaginal anomaly is an imperforate hymen, a condition in which the hymen obstructs menstrual flow or other vaginal secretions. Another vaginal anomaly is a transverse vaginal septum, which partially or completely blocks the vaginal canal. The precise cause of an obstruction must be determined before it is repaired, since corrective surgery differs depending on the cause. In some cases, such as isolated vaginal agenesis, the external genitalia may appear normal. Abnormal openings known as fistulas can cause urine or feces to enter the vagina, resulting in incontinence. The vagina is susceptible to fistula formation because of its proximity to the urinary and gastrointestinal tracts. Specific causes are manifold and include obstructed labor, hysterectomy, malignancy, radiation, episiotomy, and bowel disorders. A small number of vaginal fistulas are congenital. Various surgical methods are employed to repair fistulas. Untreated, fistulas can result in significant disability and have a profound impact on quality of life. Vaginal evisceration is a serious complication of a vaginal hysterectomy and occurs when the vaginal cuff ruptures, allowing the small intestine to protrude from the vagina. Cysts may also affect the vagina. Various types of vaginal cysts can develop on the surface of the vaginal epithelium or in deeper layers of the vagina and can grow to be as large as 7 cm. Often, they are an incidental finding during a routine pelvic examination.
== Hapten coupling == Haptens can be coupled to KLH using several methods. A simple one-step coupling can be performed using the carbodiimide crosslinker EDC to covalently attach carboxyls to primary amines. This method is the simplest to perform and the "random" orientation allows for antibody generation against all possible epitopes, but it generally results in some degree of polymerization, which decreases solubility making the conjugate more difficult to handle. KLH can be activated with the crosslinker Sulfo-SMCC, which converts lysine residues to sulfhydryl-reactive maleimide groups. A sulfhydryl-containing hapten can then be reacted with the KLH to complete the immunogen without causing polymerization. The specificity of this reaction is ideal for situations where the cysteine is located away from the desired epitope (e.g. in peptides where a terminal cysteine can be added to either end of the peptide). Maleimide activated KLH, where the first part of this two step procedure has been completed, is commercially available.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.